(Q37941807)

25 August 2017

1 reference

title

Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma (English)

1 reference

25 August 2017

1 reference

Antarpreet Kaur

1

1 reference

25 August 2017

Constantin A Dasanu

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

4 October 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

published in

1 reference

25 August 2017

volume

12

1 reference

25 August 2017

issue

16

1 reference

25 August 2017

page(s)

2493-2503

1 reference

Kinase inhibitors in cancer therapy: a look ahead

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

HER1/EGFR targeting: refining the strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

The role of HER2/neu expression and trastuzumab in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Targeted HER2 treatment in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

HER-2 amplification is highly homogenous in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Cardiotoxicity profile of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Trastuzumab in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

Correlation of c-erbB-2 protein expression and lymph node status in early gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.605354

10.1517/14656566.2011.605354

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference